

Reference:	FOI.5994.21
Subject:	Anti-VEFG treatments for eye conditions
Date of Request:	13 May 2021

Requested:

1. For the 4-month period from January to April 2021, how many patients has your trust treated with the following anti-VEGF treatments:
 - Aflibercept
 - Bevacizumab
 - Brolucizumab
 - Dexamethasone
 - Fluocinolone acetonide
 - Ranibizumab

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
 - Aflibercept
 - Bevacizumab
 - Brolucizumab
 - Dexamethasone
 - Fluocinolone acetonide
 - Ranibizumab

3. Within your trust, how many intra-vitreous injections/implants of each the following treatments have been used (for any eye condition) in the four-month period from January to April 2021:
 - Aflibercept
 - Bevacizumab
 - Brolucizumab
 - Dexamethasone
 - Fluocinolone
 - Ranibizumab

4. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from January to April 2021 for each of the following conditions:

Diabetic Macular Oedema (DMO)

 - Aflibercept
 - Bevacizumab
 - Dexamethasone
 - Ranibizumab

Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

 - Aflibercept
 - Bevacizumab
 - Dexamethasone
 - Ranibizumab

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients that received the anti-VEGF treatments listed, during the period from January to April 2021.

Treatment	Number of patients
Aflibercept	720
Bevacizumab	0
Brolucizumab	0
Dexamethasone	11
Fluocinolone acetonide	0
Ranibizumab	964

2. The UHB provides, within the table overleaf, the number of new patients that received the anti-VEGF treatments listed, during the period, January to April 2021.

Treatment	Number of patients
Aflibercept	71
Bevacizumab	0
Brolucizumab	0
Dexamethasone	9
Fluocinolone acetonide	0
Ranibizumab	87

3. The UHB provides, within the table below, the number of intra-vitreous injections/implants used for the listed treatments, during the period, January to April 2021.

Treatment	Number used
Aflibercept	1,739
Bevacizumab	0
Brolucizumab	0
Dexamethasone	31
Fluocinolone	0
Ranibizumab	2,080

4. The UHB provides, within the table below, the number of intra-vitreous injections/implants used, by eye condition and treatments listed, during the period, January to April 2021.

Treatment	Diabetic Macular Oedema	Retinal Vein Occlusion
Aflibercept	344	216
Bevacizumab	0	0
Dexamethasone	*	9
Ranibizumab	231	478

Where the figure in the table has been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding

this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/ General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.